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Background:  Yeast pyruvate kinase (PK) catalyzes the final step in glycolysis.
The enzyme therefore represents an important control point and is allosterically
activated by fructose-1,6-bisphosphate (FBP). In mammals the enzyme is found
as four different isozymes with different regulatory properties: two of these
isozymes are produced by alternate splicing. The allosteric regulation of PK is
directly related to proliferation of certain cell types, as demonstrated by the
expression of an allosterically regulated isozyme in tumor cells. A model for the
allosteric transition from the inactive (T) state to the active (R) state has been
proposed previously, but until now the FBP-binding site had not been identified.
Results:  We report here the structures of PK from yeast complexed with a
substrate analog and catalytic metal ions in the presence and absence of
bound FBP. The allosteric site is located 40 Å from the active site and is entirely
located in the enzyme regulatory (C) domain. A phosphate-binding site for the
allosteric activator is created by residues encoded by a region of the gene
corresponding to the alternately spliced exon of mammalian isozymes. FBP
activation appears to induce several conformational changes among active-site
sidechains through a mechanism that is most likely to involve significant domain
motions, as previously hypothesized.
Conclusions:  The structure and location of the allosteric activator site agrees
with the pattern of alternate genetic splicing of the PK gene in multicellular
eukaryotes that distinguishes between a non-regulated isozyme and the
regulated fetal isozymes. The conformational differences observed between the
active sites of inactive and fully active PK enzymes is in agreement with the
recently determined thermodynamic mechanism of allosteric activation through
a ‘metal relay’ that increases the affinity of the enzyme for its natural
phosphoenolpyruvate substrate.
Introduction
Pyruvate kinase (PK) catalyzes the final step in glycolysis,
producing the second of two ATP molecules generated in
the glycolytic pathway. The enzyme converts phospho-
enolpyruvate (PEP) and ADP to pyruvate and ATP
(Figure 1). This reaction is a committed step leading to
either anaerobic fermentation or oxidative phosphorylation
of pyruvate. In most cells the reaction is essentially irre-
versible (Keq = 103 to 104) and is one of the major control
points of glycolysis. The regulation of PK is important for
controlling the levels of ATP, GTP and glycolytic interme-
diates in the cell. Pk also serves as a switch between the
glycolytic and gluconeogenic pathways in certain tissues. 
Allosteric regulation of enzyme activity is a mechanism for
finely tuning biochemical reaction pathways in order to
maintain an appropriate balance of intracellular substrate
and product concentrations. Allosteric processes also allow
an enzyme’s activity to be coordinated with other cellular
reactions and signaling pathways. As the metabolic
requirements of an organism fluctuate over time and with
cell type, many organisms produce related but differen-
tially regulated forms of the same enzyme in different
tissues to satisfy disparate metabolic and growth patterns.
PK is an example of such an enzyme: it can be isolated
from mammalian tissues as four isozymes (L, R, M1 and
M2). Each isozyme exhibits different kinetic properties
that reflect the particular metabolic requirements of the
expressing tissue. In humans, two genes (the L and M
loci) encode the four different PK isozymes (Figure 2).
The L gene encodes both the L isozyme found in liver
and the R isozyme found in red blood cells, by use of a
differential promoter [1]. The M gene encodes the M1
and M2 isozymes by alternative splicing [2]. Type M1 pre-
dominates in skeletal muscle and brain, while the M2
isozyme is found primarily in the rapidly proliferating
fetal tissues. The M2 isozyme is progressively replaced
Addresses:  1Molecular and Cellular Biology
Program of the University of Washington and Fred
Hutchinson Cancer Research Center A3-023, 1124
Columbia Street, Seattle, WA 98104, USA,
2Department of Molecular and Cell Biology, Stanley
Hall, University of California, Berkeley CA 94720,
USA, 3Program in Structural Biology, Division of
Basic Sciences, Fred Hutchinson Cancer Research
Center A3-023, 1124 Columbia Street, Seattle,
WA 98104, USA, 4Department of Biochemistry and
Molecular Biology, Pennsylvania State University,
152 Davey Lab, University Park, PA 16802, USA
and 5Department of Chemistry and Biochemistry,
University of Notre Dame, Notre Dame, IN 46556,
USA. 
*Corresponding author.
E-mail:  bstoddar@fhcrc.org
Key words: allostery, alternative splicing, isozyme
shift, pyruvate kinase
Received:  15 October 1997
Revisions requested:  24 November 1997
Revisions received:  22 December 1997
Accepted:  6 January 1998
Structure  15 February 1998, 6:195–210
http://biomednet.com/elecref/0969212600600195
© Current Biology Ltd ISSN 0969-2126
Research Article 195
with the other tissue specific isozymes (M1, R and L)
during development. Type M1 is regarded as non-
regulated, because this isozyme shows predominantly
non-sigmoidal Michaelis–Menten kinetic responses to
the binding of all of its substrates and activators under
most metabolic conditions. The M2, L and R isozymes
are regarded as allosterically regulated because of their
sigmoidal kinetic responses to the binding of PEP, metal
and fructose-1,6-bisphosphate (FBP). The M2, R and L
isozymes are allosterically regulated via feed-forward acti-
vation by FBP, the product of the phosphofructokinase
(PFK) reaction. These forms are also allosterically regu-
lated via feed-back inhibition by ATP, the product of the
PK reaction, and by phosphorylation [3].
Allosteric regulation of PK is a critical feature of cell-cycle
control in rapidly proliferating tissues, because PK con-
trols both the consumption of metabolic carbon for biosyn-
thesis and the utilization of pyruvate for energy
production. Neoplasia of different tissues is associated
with re-expression of the fetal M2 isozyme [4]. Studies of
human neuroectodermal (brain) tumors have revealed a
shift from the M1 isozyme, the dominant form in the adult
human brain, to the M2 isozyme [5,6]. This shift was
found to be closely correlated with the histological
grading, growth rate, and survival after resection of the
tumor [7]. It has also been demonstrated that one charac-
teristic marker of malignant human breast tumors is the
re-expression of the allosterically regulated M2 isozyme
[8,9]. More recently, it was shown that the activity of PK
in breast cancer cells is significantly increased compared
to normal benign breast tissues [10].
Malignant cells have a high rate of aerobic glycolysis and
biosynthesis. It has been suggested that the shift towards
the M2 isozyme in tumors represents a mechanism to gain
allosteric control of the enzyme and allows for sequential
activation and inhibition of the enzyme during the cell
cycle [11,12]. Inhibition may occur so that the cellular con-
centration of glycolytic intermediates may be elevated
transiently, enhancing glucose breakdown via the hexose
monophosphate shunt and accelerating synthesis of pyrim-
idine and purine nucleotides in proliferating cells.
The amino acid sequence of PK is highly conserved
among all organisms (Figure 2). The human M1 and M2
protein sequences are encoded by an open reading frame
composed of 12 exons and differ by only the alternate
splicing of exons 9 and 10. These exon regions encode a
stretch of 56 amino acids and comprise approximately one
tenth of the total protein sequence (Figure 2). It is proba-
ble that this amino acid stretch forms the FBP-binding
site and confers the different regulatory properties of the
enzyme, as the M1 form is non-regulated and does not
bind FBP, whereas the M2 is allosterically regulated by
FBP. A putative FBP-binding site has been proposed
based on indirect methods and observations but has yet to
be structurally established [13–15]. Because the regulation
of PK activity is a fundamental process in all cellular
organisms and a classic example of the importance of
allostery and tissue-specific isozyme variation, we have
initiated an X-ray diffraction crystallographic study of
various yeast PK (YPK) complexes. YPK shows an amino
acid identity of 51% to the human M2 isoform; it also
exhibits the same pattern of allosteric regulation by FBP.
This study describes the allosteric FBP-binding site and
correlates the structural interactions at this site with mea-
sured ligand-binding energies and with patterns of differ-
ential expression of PK isozymes in mammalian tissues.
Results and discussion
Overall structural folds of YPK complexes
The structures of two YPK complexes were determined at
3.0 Å resolution as described in the Materials and
methods. The first complex is a quaternary enzyme
complex formed from YPK, Mn2+, K+ and the substrate
196 Structure 1998, Vol 6 No 2
Figure 1
(a) The reaction catalyzed by PK. (b) The chemical structures of the
substrate PEP and the substrate analog phosphoglycolate.
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Figure 2
PK isozymes and sequence alignment. (a) Expression of PK isoforms
in humans. The type M1 (non-regulated isozyme) and M2 (allosterically
regulated fetal and neoplastic isozyme) are produced from the same
gene by differential splicing of the ninth and tenth exon into the final
messenger RNA. (b) Sequence alignment of non-regulated muscle PK
isozymes (1–3; orange) and allosterically regulated isozymes (4–6;
black). Residues contacting FBP are marked by green arrows. Several
of these residues are contributed by the alternatively spliced region in
the human M1 and M2 isozyme sequence (blue box). The presence of a
conserved glutamic acid residue (blue arrow) in the unregulated
enzymes may act to prevent binding of the negatively charged FBP
and/or mimic FBP binding. The secondary structure elements for the A
and C domains are noted and labeled above the corresponding
sequences.
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  1 CAT MUS SKPHSDVGTAFIQTQ QLHAAMADTFLEHMC RLDIDSPPITARNTG IICTIGPASRSVEIL KEMIKSGMNVARLNF SHGTHEYHAETIKNV     90
  2 RAB MUS SKSHSEAGSAFIQTQ QLHAAMADTFLEHMC RLDIDSAPITARNTG IICTIGPASRSVETL KEMIKSGMNVARMNF SHGTHEYHAETIKNV     90
  3 HUM M1  SKPHSEAGTAFIQTQ QLHAAMADTFLEHMC RLDIDSPPITARNTG IICTIGPASRSVETL KEMIKSGMNVARLNF SHGTHEYHAETIKNV     90
4 HUM M2  SKPHSEAGTAFIQTQ QLHAAMADTFLEHMC RLDIDSPPITARNTG IICTIGPASRSVETL KEMIKSGMNVARLNF SHGTHEYHAETIKNV     90
  5 YEAST   --------------- -------MSRLERLT SLNVVAG-SDLRRTS IIGTIGPKTNNPETL VALRKAGLNIVRMNF SHGSYEYHKSVIDNA     67
  6 E COLI  --------------- --------------- ----------MKKTK IVCTIGPKTESEEML AKMLDAGMNVMRLNF SHGDYAEHGQRIQNL     50
1 CAT MUS RAATESFASDPIRYR PVAVALDTKGPEIRT GLIKGSGTAEVELKK GATLKITLDNAYMEK CDENVLWLDYKNICK VVEVGSKVYVDDGLI    180
  2 RAB MUS RTATESFASDPILYR PVAVALDTKGPEIRT GLIKGSGTAEVELKK GATLKITLDNAYMEK CDENILWLDYKNICK VVDVGSKVYVDDGLI    180
  3 HUM M1  RTATESFASDPILYR PVAVALDTKGPEIRT GLIKGSGTAEVELKK GATLKITLDNAYMEK CDENILWLDYKNICK VVEVGSKIYVDDGLI    180
 4 HUM M2  RTATESFASDPILYR PVAVALDTKGPEIRT GLIKGSGTAEVELKK GATLKITLDNAYMEK CDENILWLDYKNICK VVEVGSKIYVDDGLI    180
  5 YEAST   RKSEELYPG-----R PLAIALDTKGPEIRT GTT--TNDVDYPIPP NHEMIFTTDDKYAKA CDDKIMYVDYKNITK VISAGRIIYVDDGVL    150
  6 E COLI  R-NVMSKTG-----K TAAILLDTKGPEIRT MKLE--GGNDVSLKA GQTFTFTTDKSVIG- -NSEMVAVTYEGFTT DLSVGNTVLVDDGLI    130
1 CAT MUS SLLVKEKGAD-FLVT EVENGGSLGSKKGVN LPGAAVDLPAVSEKD IQDLKFGVEQDVDMV FASFIRKASDVHEVR KVLGEKG-KNIKIIS    268
  2 RAB MUS SLQVKQKGPD-FLVT EVENGGFLGSKKGVN LPGAAVDLPAVSEKD IQDLKFGVDEDVDMV FASFIRKAADVHEVR KILGEKG-KNIKIIS    268
  3 HUM M1  SLQVKQKGAD-FLVT EVENGGSLGSKKGVN LPGAAVDLPAVSEKD IQDLKFGVEQDVDMV FASFIRKASDVHEVR KVLGEKG-KNIKIIS    268
 4 HUM M2  SLQVKQKGAD-FLVT EVENGGSLGSKKGVN LPGAAVDLPAVSEKD IQDLKFGVEQDVDMV FASFIRKASDVHEVR KVLGEKG-KNIKIIS    268
  5 YEAST   SFQVLEVVDDKTLKV KALNAGKICSHKGVN LPGTDVDLPALSEKD KEDLRFGVKNGVHMV FASFIRTANDVLTIR EVLGEQG-KDVKIIV    239
  6 E COLI  GMEVTAIEGN-KVIC KVLNNGDLGENKGVN LPGVSIALPALAEKD KQDLIFGCEQGVDFV AASFIRKRSDVIEIR EHLKAHGGENIHIIS    219
1 CAT MUS KIENHEGVRRFDEIL EASDGIMVARGDLGI EIPAEKVFLAQKMMI GRCNRAGKPVICATQ MLESMIKKPRPTRAE GSDVANAVLDGADCI    358
  2 RAB MUS KIENHEGVRRFDEIL EASDGIMVARGDLGI EIPAEKVFLAQKMII GRCNRAGKPVICATQ MLESMIKKPRPTRAE GSDVANAVLDGADCI    358
  3 HUM M1  KIENHEGVRRFDEIL EASDGIMVARGDLGI EIPAEKVFLAQKMMI GRCNRAGKPVICATQ MLESMIKKPPPTRAE GSDVANAVLDGADCI    358
4 HUM M2  KIENHEGVRRFDEIL EASDGIMVARGDLGI EIPAEKVFLAQKMMI GRCNRAGKPVICATQ MLESMIKKPRPTRAE GSDVANAVLDGADCI    358
  5 YEAST   KIENQQGVNNFDEIL KVTDGVMVARGDLGI EIPAPEVLAVQKKLI AKSNLAGKPVICATQ MLESMTYNPRPTRAE VSDVGNAILDGADCV    329
  6 E COLI  KIENQEGLNNFDEIL EASDGIMVARGDLGV EIPVEEVIFAQKMMI EKCIRARKVVITATQ MLDSMIKNPRPTRAE AGDVANAILDGTDAV    309
  1 CAT MUS MLSGETAKGDYPLEA VRMQHLIAREAEAAM FHRKLFEELVRGSSH STDLMEAMAMGSVEA SYKCLAAALIVLTES GRSAHQVARYRPRAP    448
  2 RAB MUS MLSGETAKGDYPLEA VRMQHLIAREAEAAM FHRKLFEELARSSSH STDLMEAMAMGSVEA SYKCLAAALIVLTES GRSAHQVARYRPRAP    448
  3 HUM M1  MLSGETAKGDYPLEA VRMQHLIAREAEAAM FHRKLFEELVRASSH STDLMEAMAMGSVEA SYKCLAAALIVLTES GRSAHQVARYRPRAP    448
4 HUM M2  MLSGETAKGDYPLEA VRMQNLIAREAEAAI YHLQLFEELRRLAPI TSDPTEATAVGAVEA SFKCCSGAIIVLTKS GRSAHQVARYRPRAP    448
  5 YEAST   MLSGETAKGNYPINA VTTMAETAVIAEQAI AYLPNYDDMRNCTPK PTSTTETVAASAVAA VFEQKAKAIIVLSTS GTTPRLVSKYRPNCP    419
  6 E COLI  MLSGESAKGKYPLEA VSIMATICERTDRVM NSRLEFNNDNR---- KLRITEAVCRGAVET AEKLDAPLIVVATQG GKSARAVRKYFPDAT    395
1 CAT MUS IIAVTRNHQTARQAH LYRGIFPVVCKDPVQ EAWAEDVDLRVNLAM NVGKARGFFKHGDVV IVLTGWRPGSGFTNT MRVVPVP            530
  2 RAB MUS IIAVTRNHQTARQAH LYRGIFPVVCKDPVQ EAWAEDVDLRVNLAM NVGKARGFFKKGDVV IVLTGWRPGSGFTNT MRVVPVP            530
  3 HUM M1  IIAVTRNPQTARQAH LYRGIFPVLCKDPVQ EAWAEDVDLRVNFAM NVGKARGFFKKGDVV IVLTGWRPGSGFTNT MRVVPVP            530
 4 HUM M2  IIAVTRNPQTARQAH LYRGIFPVLCKDPVQ EAWAEDVDLRVNFAM NVGKARGFFKKGDVV IVLTGWRPGSGFTNT MRVVPVP            530
  5 YEAST   IILVTRCPRAARFSH LYRGVFPFVFEKEPV SDWTDDVEARINFGI EKAKEFGILKKGDTY VSIQGFKAGAGHSNT LQVSTV-            500
  6 E COLI  ILALTTNEKTAHQLV LSKGVVPQLVK---E --ITS-TDDFYRLGK ELALQSGLAHKGDVV VMVSGALVPSGTTNT ASVHVL-            470
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analog phosphoglycolate (PG). The second complex is a
quinternary enzyme complex formed from YPK, Mn2+,
K+, PG and the allosteric activator FBP. Both enzyme
complexes were co-crystallized with substrates and activa-
tors to yield closely related monoclinic space groups with
two monomers per asymmetric unit. The structures of
both complexes are homotetramers and have overall con-
formations similar to the previously solved structures of
the non-allosterically regulated muscle enzymes [16,17].
Each subunit of YPK is composed of four separate
domains (Figure 3). The first domain, N, is a short α-
helical stretch at the N terminus (residues 1–18) that is
also present in the non-regulated muscle enzymes but is
not present in the similarly FBP-activated enzyme from
Escherichia coli [15]. The second domain, A, is the catalytic
domain and is formed by two separate stretches of amino
acids (residues 19–88 and 189–360) that fold together into
the common parallel (α/β)8 barrel motif with two addi-
tional α helices. The third domain, B, is the capping
domain (residues 89–188) and is a small nine-stranded β-
barrel motif that forms a cap over the active site. Finally,
the C domain, or the regulatory domain, is located at the
C terminus of the protein (residues 361–500) and has an
α/β open-sheet motif. In both YPK structures no ordered
electron density is observable for the residues (11–16)
connecting the N and A domains. In addition, in the quin-
ternary complex, residues 160–161 of the B domain are
not observable in either subunit, and residues 99–100 are
not observable in one subunit. Conversely, in the quater-
nary complex without FBP, much of a long protein loop
forming part of the allosteric binding site (residues
446–452) is disordered, as is the last loop of the C domain
(485–493). Because these regions are visible in the pres-
ence of bound FBP and several residues from each loop
contact the allosteric activator, this binding site appears to
undergo a disorder→order transition during the allosteric
activation of YPK (see below).
Allosteric effector FBP-binding site
A putative FBP-binding site for allosterically regulated PK
has been proposed from a variety of indirect methods and
from an analysis of the structures of the unliganded
enzymes from cat muscle and E. coli [13–15]. The location
of the FBP site was proposed to be in a cleft between the
A and C domains. The crystal structure of the fully
ligated, quinternary complex of YPK reveals that the FBP
site actually lies completely within the C domain. One
molecule of FBP was found in a binding pocket within the
C domain of each monomer of the enzyme when co-crys-
tallized with FBP. The density for each bound activator
molecule was strong and unambiguous, as observed in
unbiased Fo–Fc difference maps that were calculated after
refinement of protein coordinates (Figure 4). FBP has
been shown to display negative cooperativity in binding to
YPK, with a stoichiometry of between three and four mol-
ecules bound per enzyme tetramer (Figure 5) [18]. In the
crystal structure, any differential occupancy of FBP-bound
sites is averaged over the four sites.
The electron density of the bound FBP supports model-
ing and refinement of the activator in the β-furanose form
(Figure 4). This anomer was previously suggested as the
activating stereoisomer of the compound on the basis of
several biochemical studies [19–21].
The allosteric site for FBP is located ≅ 40 Å away from
the active site within the same monomer. The FBP site
is located in a pocket formed from a loop (residues
402–407) between the Cβ1 strand and the Cα3 helix, and
from the first two turns of the Cα5 helix (Figure 3). This
helix immediately follows a disordered loop (residues
446–452) that becomes ordered upon the binding of FBP
(Figure 3). FBP binds in a pocket at this site and is
almost completely buried. The 1′-phosphate group of
FBP makes a strong 2.8 Å electrostatic interaction with
Arg459. The 6′-phosphate makes a series of hydrogen
bonds to the sidechains of Ser402, Ser404, and Thr407
(Figure 4). This sequence (Ser402-Thr-Ser-Gly-Thr-
Thr407) thus constitutes a well defined phosphate-
binding pocket in the enzyme. The sugar ring of the
FBP molecule is deeply sequestered within the binding
cavity, making a pair of hydrogen-bond contacts between
hydroxyl oxygens and mainchain atoms of residues 483
and 491.
One additional interaction between the enzyme and FBP
is formed by Trp452 and the furanose ring of FBP. Such
an interaction would explain the large quenching and red
shift in the Trp452 fluorescence spectrum that occur upon
FBP binding [22], as well as the observed decrease in
solvent accessibility of Trp452 [18].
Residues 446–452, including the tryptophan residue, are
disordered in the absence of bound FBP. This sequence is
positioned between the Cβ3 strand and the Cα5 helix and
forms virtually no interactions with other protein residues
allowing it to swing freely in solvent. This mobile loop is
highly variable among organisms in both its length and its
amino acid composition [18]. Sequence alignments indi-
cate that the longest loops occur in enzymes isolated from
fungi [18]; this loop is slightly shorter in the enzyme from
higher eukaryotes, and shortest in the enzyme from proto-
zoa and bacteria.
A comparison of the FBP-binding site of YPK with the
same region in other PK structures reveals significant differ-
ences. In the quaternary structure of YPK determined in
the absence of FBP, no electron density was observed for
the residues in the above mobile loop at any stage of the
structure determination and refinement. The turn of
residues 487–493 is also disordered in the quaternary struc-
ture. The same site in the structure of the rabbit muscle
198 Structure 1998, Vol 6 No 2
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Figure 3
YPK structural model. (a) Stereo view of the
tetrameric YPK with bound PG and bound
FBP. The A domain is colored red, and the B
and C domains are colored green and blue,
respectively. Residues corresponding to the
sequence encoded by the alternatively spliced
exon in humans are colored purple; bound
ligands are shown as gray van der Waals
models. (b) Stereo view of a single YPK
subunit showing the distance and relationship
between the allosteric and active sites. PG,
Mn2+ and K+ are bound in the active site
between the A and B domains and FBP is
bound in the allosteric site in the C domain.
(c) Stereo view of the allosteric site with
bound FBP. The arrow indicates the mobile
loop that is disordered in the quaternary
structure (i.e. without bound FBP).
enzyme, which is not regulated by FBP, shows a narrower
pocket with the mobile loop shifted inwards. The turn of
residues 487–493 in the rabbit structure is folded over the
allosteric site thereby closing it off to FBP binding. The
allosteric site in the E. coli apoenzyme structure differs pri-
marily in that the mobile loop is truncated by six residues.
Thus, there is no equivalent residue to Trp452 which con-
tacts the sugar ring of FBP. Nevertheless, the phosphate-
binding pocket (residues 402–407) for the 1′-phosphate of
FBP is present in a similar conformation. Thr406, which is a
lysine residue in the E. coli sequence, has previously been
implicated in FBP binding by chemical modification and as
a result of studies with the E. coli enzyme [14,23]. There is,
however, no equivalent residue to Arg459 which binds the
6′-phosphate of FBP; in E. coli PK the Cα5 helix that
donates this sidechain is shifted by over 2 Å away from the
allosteric site.
The allosteric site for FBP is consistent with the location
of the residues encoded by the alternatively-spliced exon
200 Structure 1998, Vol 6 No 2
Figure 4
The FBP-binding site. (a) Stereo view of the
allosteric activator binding site with bound
FBP. Electron density (2Fo–Fc) is shown for
FBP (yellow stick model) at a 1.5σ contour
level. (b) Interaction of Arg459 and the FBP
1′-phosphate (shown in yellow). (c) Interaction
of the FBP 6′-phosphate (yellow) with
residues from the allosteric exon (403–407).
(d) Schematic of the FBP-binding
interactions. Interactions are shown as
dashed blue lines and their distances are
given in Å. Thr403 is converted to a glutamic
acid in all known, sequenced non-allosteric
isozymes. This residue is found in the
alternatively spliced exon for the human M2
isozyme. As a glutamic acid, this residue
could either hinder FBP binding, through
steric and electrostatic overlap, or act to
mimic the effect of FBP binding.
in mammalian PK isozymes. This stretch of amino acids,
residues 349 to 405 in the yeast sequence, dictates the reg-
ulatory properties of the human muscle isozymes M1 and
M2 (Figure 2). Within this region, residues 401 to 404 form
one side of the binding cleft and a phosphate-binding
pocket for the 1′-phosphate of FBP. These residues corre-
spond to the last five amino acids encoded by the exon
that is alternatively spliced. Ser402, which makes a hydro-
gen bond to the FBP 1′-phosphate, is conserved as a
serine or threonine in mammalian M2 PK sequences. Con-
versely, residue 403, which is a threonine in the yeast
structure and a lysine in the human M2 isozyme, is strictly
conserved in non-regulated PK isozymes as a glutamic
acid. This residue could hinder FBP binding through
steric and electrostatic overlap and also could act in mim-
icking the effect of FBP binding.
The active site and binding of PG and catalytic metals
PG is a structural analog of PEP and has been shown to be
a product of the YPK-catalyzed phosphorylation of
glycolate by ATP [24] (Figure 1). In addition to being a
substrate for the reverse reaction of YPK, PG is also a
potent competitive inhibitor of PEP for the forward
reaction (Figure 6a). The PG inhibition data is best fit to a
model for linear competitive inhibition and the resulting
steady-state kinetic parameters are Vmax = 72.3 ± 0.7
units/mg, KM,PEP = 19.3 ± 0.6 µM and KI,PG = 20.9 ± 0.8.
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Figure 6
Inhibition and activation of YPK by PG. (a) Double reciprocal plot of
the activity of YPK in the presence of 10 mM FBP measured by varying
the concentration of PEP at different fixed concentrations of PG. PEP
concentrations varied from 5 to 200 µM and PG concentrations were
0 (l), 10 (l), 20 (t), 40 (t), 100 (n), and 160 (n) µM, respectively.
The data were best fit to a competitive inhibition model and the
resulting kinetic constants are described in the text. (b) Plot of the
relative percentage activation of YPK by PG in the absence of FBP.
PEP concentrations were fixed between 5 and 75 µM (see insert) and
PG concentrations were varied between 0 and 50 µM. The percentage
activation was calculated by dividing the rates in the absence of PG by
the rates in the presence of PG. At subsaturating PEP concentrations
PG activates YPK and at high PEP concentrations PG inhibits YPK
(see text for a detailed explanation). The lines are smooth curves
through the data.
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00

200
175
150
125
100
75
50
1/
v 
(u
ni
ts
/m
g)
–1
A
ct
iv
at
io
n 
(%
)
1/[PEP] (µM)–1
[Phosphoglycolate] (µM)
0.00 0.05 0.10 0.15 0.20 0.25
(a)
(b)
0 10 20 30 40 50
Structure
Zero PGA
5 µM PEP
10 µM
15 µM
20 µM
25 µM
35 µM
50 µM
75 µM
Ac
tiva
tio
n
Inhibition
Figure 5
Binding effects of FBP. Scatchard binding plot for FBP in the
presence of PEP and Mn2+. The solid curve was generated by a best
fit of the data to the Hill equation; the dotted curve represents the best
fit of the data to the Adair equation, r = [FBP]bound / [YPK]total. Binding
assays reproducibly indicate a combination of positive and negative
cooperativity between binding sites, with a saturated stoichiometry of
approximately three FBP molecules bound per tetramer under various
conditions.
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The equivalence of KM and KI suggests that the binding
modes of PEP and PG with YPK are very similar. In the
absence of FBP and at subsaturating PEP concentrations,
PG acts as an allosteric activator (Figure 6b). The KNF
(Koshland–Nemethy–Filmer) or sequential model for the
allosteric, homotropic activation of an enzyme by its sub-
strate predicts that a substrate analog or competitive
inhibitor may activate the enzyme in the absence of an
allosteric activator under subsaturating substrate condi-
tions [25]. The data in Figure 6 shows that at low, subsatu-
rating PEP concentrations and at low PG concentrations,
PG binds to YPK and increases the affinity of PEP for the
remaining sites thereby increasing the activity. This is
illustrated by the upward-curving portion of the data that
rises above 100% activation. As PG concentrations are
increased, it competes against PEP for the catalytic sites
on the enzyme surface (shown by the downward-curving
data). When PEP concentrations are saturating, PG com-
petes for PEP at all of the active sites. The inhibition and
activation data indicate that PG does indeed mimic the
binding and allosteric activation of PEP.
Both of the crystallographically unique substrate-binding
sites are occupied by bound PG, Mn2+, and K+ (Figure 7).
The active site is located in a cleft between the A and B
domains, as shown previously in both the cat and rabbit
muscle enzymes [16,17,26]. Electron density associated
with PG, Mn2+, and K+ appears in this same region of the
map for YPK. PG was modeled into the density in a posi-
tion analogous to that of pyruvate in the active site of
rabbit muscle PK (complexed with Mn2+, K+ and pyru-
vate) [16]. The electron density for the phosphate group
was very strong (>4σ). The position of the phosphate
group is consistent with that of the 2-keto oxygen of pyru-
vate, which is formed after phosphoryl transfer from PEP
to ADP. The orientation of PG and of its phosphate group
also appears very similar to that of phospholactate in the
recent rabbit M1 isozyme structure complexed in the
presence of Mn2+, and K+ [26].
The electron density for the phosphate of PG places it in
an electrostatic pocket formed by the positively charged
sidechains of Arg49 and Lys269, and the monovalent and
divalent metal ions, K+ and Mn2+, that are essential for
enzymatic activity (Figure 7). Arg49 and Lys269 are 100%
conserved in all PKs studied to date [18]. This positively
charged electrostatic pocket would allow for the dissipa-
tion of the negative charges of the phosphate group during
approach of the transition state, thereby making the phos-
phorous atom more electrophilic and susceptible to nucle-
ophilic attack by ADP [27]. Thus, Arg49, Lys269, K+,
Mn2+, and possibly Ser213, may serve to position and acti-
vate the phosphoryl transfer process.
Phosphoryl transfer has been shown to precede proton
transfer and occurs via an ‘in-line’ associative pathway
with inversion of configuration of the phosphorous center
[28,29]. The products of the phosphoryl transfer process
are proposed to be ATP and the enolate of pyruvate
[30,31]. This intermediate is proposed by a number of
studies to be protonated by either Lys240 or by Thr298
[16]. These residues are 100% conserved in all PKs and
our structure supports the possibility that either residue
may serve as a proton donor. A more definitive assignment
of the proton donor will have to await further chemical,
biophysical and site-directed mutagenesis studies.
There are some small differences in the orientation of the
PG versus pyruvate in the rabbit M1 structure (Figure 8).
These differences are likely to be due to the negatively
charged phosphate group of PG: its interaction with a pos-
itively charged binding pocket anchors it in a different ori-
entation compared to the uncharged carbonyl oxygen at
the analogous position in pyruvate. Moreover, PG lacks
the methyl group of pyruvate which will also influence its
relative orientation. As the carboxylate moiety is con-
served between both PG and pyruvate, its position may be
strongly dependent on the nature of the other atoms
attached to the ligand.
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Figure 7
Stereo view of the active site of YPK with
bound PG, Mn2+ and K+. An electron-density
(2Fo–Fc) map is shown at the 1.5σ contour
level (red) and the 3.5σ contour level (blue).
Atoms are shown in standard colors and
metal ions are depicted as gray spheres.
All known PKs have an absolute requirement for two diva-
lent metal ions per monomer, usually Mg2+ or Mn2+. In
addition most PKs require one monovalent metal ion per
monomer for activity, usually K+ or NH4+ [32,33]. One of
the divalent metal ions binds to the free enzyme and facil-
itates the binding of the substrate PEP while the other
divalent metal binds to the enzyme via a complex with the
substrate ADP [22,34–36]. YPK has an absolute require-
ment for both divalent and monovalent cations. The
enzyme-bound divalent metal ion has been shown
recently to trigger the allosteric activation of YPK through
a metal ion mediated allosteric relay mechanism [22,36].
The enzyme-bound Mn2+ lies at the top of the α/β barrel
in both the quaternary and quinternary structures of YPK.
The coordination sphere of Mn2+ is approximately octahe-
dral and is formed by two carboxylate sidechain oxygens
of Glu242 (2.1 Å) and Asp266 (2.1 Å), one of the carboxy-
late oxygens of PG (2.0 Å), and the phosphoester oxygen
of PG (2.1 Å). Two water molecules presumably complete
the coordination but are not visible in the electron density
at this resolution. The sidechain carboxylates of Glu242
and Asp266 chelate to the metal via their anti lone pairs
[37]. The coordination sphere of Mn2+ observed in the
yeast structures is similar to the coordination sphere of
Mn2+ found in the rabbit muscle PK structures [16,26].
The Mn2+ site lies approximately 5.7 Å away from the K+
site in both the quaternary and quinternary YPK struc-
tures. This is consistent with the range of distances
between the enzyme-bound Mn2+ and Tl+ sites of various
YPK complexes calculated from NMR data [38]. The K+
site is formed from residues located in two highly con-
served stretches of amino acids. The first amino acid
stretch, Asn51-Phe-Ser-His-Gly55, is 100% conserved in
28 PK sequences [18]. K+ coordinates with the amide
oxygen of Asn51 (2.9 Å) and with the sidechain oxygen of
Ser53 (3.4 Å). The second amino acid stretch, Leu83-Asp-
Thr-Lys-Gly-Pro-Glu-Ile-Arg-Thr92, is 100% conserved in
26 PK sequences and, considering only the italicised
residues, 100% conserved in 28 PK sequences [18]. K+
coordinates to a sidechain oxygen of Asp84 (2.8 Å) and to
the backbone carbonyl oxygen of Thr85 (3.25 Å). Interest-
ingly, the two PKs that differ in this stretch, enzymes iso-
lated from E. coli (type II) and Corynebacterium glutamicum,
are not activated by monovalent cations [39,40]. The
sequence of this region in these two enzymes is Ala83-
Asp-Leu-Gln-Gly-Pro-Lys-Ile-Arg-Val/Leu92. The substi-
tution of lysine for glutamate at position 89 may activate
the enzyme if the ε-NH3+ group of lysine takes the role of
either K+ or NH4+. We tested this possibility by modeling
a lysine residue into the position of Glu89, where one of
its carboxylate oxygens is 5.4 Å away from the K+ site and
4.5 Å away from the phosphate site. Substituting a lysine
residue for Glu89 places the ε-amino group within 2.4 Å of
the existing K+ site and in direct contact (3.0–3.3 Å) with
one of the phosphate oxygens of the substrate. In addi-
tion, the ε-amino group position can be stabilized by
forming a hydrogen bond (2.7 Å) with the absolutely con-
served residue Ser53. Thus, a lysine residue in this posi-
tion may indeed mimic the monovalent cation and assist
in stabilizing phosphoryl transfer.
The nucleotide-bound Mn2+ site was not observed in elec-
tron density difference maps. This is consistent with the
fact that Mn2+ binding to the second metal site is highly
dependent on the presence of ADP [41,42]. Ligands that
may serve to bind the nucleotide-bound metal and associ-
ated phosphates of ADP are Asn51 and His54, also part of
the highly conserved loop between the Aβ2 strand and the
Aα2 helix, and possibly Arg91, which is close to His54.
These residues are close to the phosphate pocket of PG.
Arg91 is 100% conserved in all PK sequences and it makes
a hydrogen bond with the sidechain of Asp89 described
above. Histidine residues have been proposed to be close
to the nucleotide-bound metal site and to the adenine-
binding site [43]. Furthermore, the nucleotide-bound
Mn2+ site has been calculated from NMR studies to be
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Figure 8
Stereo view comparison of PK active sites.
The figure shows a superposition of the PK
active sites from yeast with bound PG, Mn2+
and K+ (blue), rabbit muscle with bound
pyruvate, Mn2+ and K+ (red) and the E. coli
apoenzyme (green).
approximately 5–5.5 Å away from the enzyme-bound diva-
lent cation site, approximately 5.9 Å away from the phos-
phate of PEP, and approximately 6.7 Å away from the
monovalent cation site [44–46]. The conserved Asn51-
Phe-Ser-His-Gly55 loop is located in a position consistent
with these distances and may therefore participate in
binding the Mn2+AD(T)P complex.
It is difficult, however, to infer a precise location of the
substrate AD(T)P from our structure or from the results
of chemical modification studies. Three lysine residues of
PK have been implicated in binding and/or catalysis of
AD(T)P based on chemical modification studies of the
enzyme with dialdehyde-AD(T)P. One homologous
lysine residue that is subject to chemical modification is
Lys337 [44–49]. This lysine is conserved in 22 out of 25
PK sequences and is in equivalent positions in all PK
enzyme structures [18]. The residue is located near the
entrance to the active site and resides in a loop between
the two Aα8 helices, which is approximately 13 Å away
from the phosphate of PG. The two additional lysine
residues identified by chemical modification in the E. coli
enzyme are Lys194 and Lys196 (E. coli sequence).
Lys194 is present in all PK’s, except the R and L forms
encoded by the L gene in mammals, while Lys196 is
present in only a few PK species. These two residues are
over 20 Å away from Lys337. Without direct structural
observation of ADP at the active site, it is difficult to
ascertain how the substrate could occupy two completely
different locations. What is notable, however, is that PK
does not seem to show an absolute specificity towards any
individual nucleotide diphosphate as ADP, GDP, UDP,
IDP, TDP, and CDP can all serve as substrates
[39,50–52]. This fact, together with NMR data on the
conformation of enzyme-bound MgATP, suggest that the
nucleotide portion of the NDP substrate may exhibit a
high degree of mobility [53]. 
The structures of the active sites of YPK in the presence
and absence of bound-FBP are extremely similar. The
root mean square (rms) deviation between all atoms in
these active sites is less than 1 Å. These results indicate
that the structural effects of FBP binding are similar to the
effects of cooperative substrate binding, in that either
FBP or PEP can drive the enzyme towards a predomi-
nantly activated conformation. The simultaneous binding
of Mn2+ and PEP to the YPK–K+ complex is favored by
–3.8 kcal/mol over the sum of their independent binding
free energies. Similarly, the simultaneous binding of
Mn2+, PEP and FBP to the YPK–K+ complex is favored by
–6.6 kcal/mol [36]. The difference in coupling free energy
of –2.8 kcal/mol between formation of the quaternary and
quinternary complexes suggests that the small structural
differences in the active-site complexes may be significant
in terms of binding energies and affinities, although their
steady-state catalytic rates are the same [22].
YPK exhibits little or no difference in the catalytic rates
between the FBP-bound and unbound complexes under
saturating substrate concentrations, in agreement with the
structural comparison of the two complexes described
above. However, this may be true only with its physiologi-
cal substrate PEP. YPK-catalyzed phosphorylation of gly-
colate by ATP has been shown to occur only in the
presence of FBP [24]. Differences in the microscopic rate
constants for proton and phosphoryl transfer between PEP
and ADP have been shown to be different for YPK in the
presence and absence of FBP, even though the overall
steady-state kinetic rates are the same [54]. PEP-bound
YPK may undergo additional conformational changes at its
active site upon the binding of FBP. We propose that
these changes may fine-tune substrate alignment and
hence the individual rate constants for both proton and
phosphoryl transfer. The conformational changes and
their effect on rate may be more dramatic with alternate
substrates. Small conformational changes in protein struc-
ture and substrate orientation have been shown recently
to have dramatic effects on the rate constants for enzyme-
catalyzed reactions [55].
Allosteric activation of PK
YPK is regulated allosterically by a number of physiologi-
cal effectors including PEP, ATP, H+, Mn2+, K+ and FBP.
Many of the interactions between these ligands and the
enzyme involve both homotropic and heterotropic cooper-
ativity [22,56,57]. YPK behaves as a classical ‘K type’
system, indicating that the substrates and allosteric activa-
tors modulate the binding affinities of each other. The
allosteric activator FBP was originally thought to regulate
YPK by ‘directly’ influencing the affinity of the enzyme
for the substrate PEP. It was recently shown, however,
that the major driving force for YPK regulation by FBP
occurs through the enzyme-bound divalent metal via an
allosteric relay mechanism [22,36].
A hypothesis regarding the mechanism of allosteric com-
munication between the FBP- and PEP-binding sites has
been previously proposed by comparing the structure of an
inactivated (T state), PK structure from E. coli to the
unregulated, active structures of PK from mammalian
muscle tissues [15,58]. This model involves rotations of the
catalytic and C-terminal domains of the enzyme by 17° and
15°, respectively, relative to the principle symmetry axes of
the enzyme tetramer. It was proposed that highly con-
served residues at the subunit interfaces (many of which
are contributed by the alternatively spliced exon in
mammals) couple conformational changes in the allosteric
binding site to corresponding conformational changes in
the active site, leading to an increase in the affinity for the
PEP substrate. The recent structure of rabbit muscle PK
complexed with phospholactate and metals in its active
site also supports the concept of domain movements
playing a functional role in the enzyme’s activity [26]. It is
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somewhat daunting to propose a specific mechanism of
allosteric communication based on the comparison of inac-
tivated and active enzyme from prokaryotic and eukaryotic
sources (44% sequence identity between yeast and E. coli
PK’s). A fully validated, unambiguous model awaits the
direct comparison of the T and activated (R) state enzymes
from the same species as well as the structure of PK from
that species complexed only with FBP. Further modeling
of the mechanism of allosteric communication is, however,
facilitated by our identification of the exact location of the
FBP-binding site.
In order to begin modeling the mechanism of allosteric
communication, the structures of the FBP-bound YPK
monomer, the FBP-regulated apoenzyme monomer from
E. coli, and the pyruvate-bound, unregulated enzyme
monomer from rabbit muscle were superimposed, and the
active-site structures directly compared. The overall rms
deviation between Cα atoms of YPK and rabbit M1 PK is
1.95 Å, and 3.02 Å between YPK and E. coli apo PK. In
both cases these differences arise mainly from rotations of
domains B and C relative to the A domain. (Rms deviation
between the A domains of YPK and these enzymes is less
than 1.17 Å for both structures). There are two significant
differences between the activated and inactivated cat-
alytic sites (Figure 8), consisting of previously noted
movements of active-site residues Asp266 and Phe214
[15,26]. Phe214 may help in increasing the hydrophobicity
contrast function for the metal [59], serve to pack and
align the substrates correctly, and may interact directly
with ADP. Asp266 directly coordinates the bound divalent
cation and triggers the allosteric response in agreement
with the measured thermodynamic coupling parameters
for allosteric activation of YPK by metal binding [22,36].
How might FBP binding trigger the large conformational
change hypothesized on the basis of these different struc-
tures? The overall nature of the conformational change
consists of subunit rotations centered around distinct
pivot points at the tetramer interfaces (Figure 9). In the
YPK structure, the interface that is closest to the FBP-
binding site contains two pairs of symmetry-related
helices of the C domain packed against one another (Cα1
against Cα1′, and Cα2 against Cα2′). Salt bridges
between Arg369 and Asp366′ of a neighboring subunit (as
well as the reverse Asp366 and Arg369′ interaction) stabi-
lize the interaction between helices Cα1 and Cα1′ of
YPK; these helices are truncated and disordered in the E.
coli structure and do not contribute to the tetramer inter-
face. In contrast, helices Cα2 and Cα2′ appear to rotate
and alter their packing contacts as a result of enzyme acti-
vation. In yeast the Cα2–Cα2′ interaction is created by
hydrogen bonds between Glu392 and Thr376′ (and vice
versa) and hydrogen bonds between the sidechain of
Ser385 and the carbonyl of Ser385′ (and vice versa).
These helices are separated by over 4 Å in the E. coli
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Figure 9
Stereo view of (a) one of the ‘dimer-of-dimers’
interfaces of the YPK activated tetramer (blue)
and (b) the E. coli inactive tetramer (yellow).
The human allosteric exon-encoded region is
colored in purple on the yeast structure;
bound ligands are shown as gray van der
Waals models. The interacting sidechains
from Cα1 and Cα2 are shown in the yeast
structure. Sidechains from these helices in the
E. coli structure are separated by over 4 Å.
This region is pivotal in the allosteric transition
between active and inactive states.
tetramer and do not contribute to the tetramer interface.
A small rotation and shear of the E. coli Cα2 helices
inwards towards the tetramer center, forming a structure
similar to activated PK, would create symmetry-related
salt bridges between Arg360 and Glu364 of the E. coli
structure. The differences between the T and R state can
be accounted for in part by such a rotation. The Cα2
helices in the tetramer interface are directly adjacent to
the residues forming the FBP-binding pocket within the
primary sequence and 3D structure of the protein
(Figure 3c). Specifically, the end of helix Cα2 occurs at
Gln393 and is followed by a short five-residue β strand
(Cβ1) which is then immediately followed by the protein
loop that binds the 1′-phosphate of FBP. 
The third part of the dimer-of-dimers interface in this
region is formed by an extension of the C domain’s central
five-stranded β sheet across the interface, with Cβ5 and
Cβ5′ forming an antiparallel interaction. When this now
ten-stranded extended β sheet from E. coli and yeast is
superimposed, it is obvious that the Cβ1 and Cβ1′ strands
are slightly twisted and translated in the sheet, in order to
make room for FBP binding at their C-terminal ends. This
movement is propagated to the Cα2 helix and is likely to
be responsible for communication of FBP binding to the
tetramer interface. All of the residues within Cα1, Cα2,
Cβ1, and the phosphate-binding loop are altered in
humans by alternative splicing of the ninth and tenth
exons in the PK M gene.
Changes at the allosteric site also include two disordered
loops (residues 445–455 and residues 485–492) surround-
ing the FBP molecule, which become more ordered upon
FBP binding. Two FBP molecules lie directly across from
each other at the interface of the C domains and are ~20 Å
apart. The changes in this region are likely to be responsi-
ble for the positive and negative cooperativity that is
observed for FBP upon binding to the YPK–K–Mn2+–PEP
complex (Figure 5).
The interface between the A domains of opposite sub-
units is also different in the yeast and E. coli structures.
The differences are similar to those noted in the compari-
son the of the bacterial and rabbit muscle enzymes and
relate to the contacts made by Arg312 [15]. In the inactive
E. coli enzyme Arg312 forms a salt bridge with Asp317′,
whereas in the yeast and rabbit structure Arg312 points
towards Asp147′ from the opposite B domain (although
this distance is >3 Å in both the rabbit and yeast struc-
tures). In the yeast structure Asp317 now forms a salt
bridge with Arg264′. These rearrangements are related to
a change in the relative orientation of the opposing cat-
alytic A domains.
Mutational analysis further supports the importance of
these interfaces for enzyme regulation. In yeast, the
site-directed mutation of Ser385→Pro produces a protein
which requires FBP for enzyme activity [60]. This
residue makes important hydrogen bonds at the Cα2–
Cα2′ interface. A mutation in the rat M1 isozyme,
Ala369→Arg, causes this non-regulated muscle enzyme to
exhibit sigmoidal kinetics [61]. An arginine is conserved
at this position in all eukaryotic allosterically regulated
isozymes, and forms part of a salt bridge between
Cα1–Cα1′ in the yeast structure. Mutations in the human
R isozyme expressed in red blood cells are the most
common cause of hereditary nonspherocytic hemolytic
anemia [62]. These mutations cluster at the active site, A
domain interface and C domain [58]. In the C domain, 14
different mutations that cause this condition have been
found: six are encoded in the sequence corresponding to
the alternatively spliced exon of the human M gene. Two
of these mutations are notable in that they impair
allosteric activation of the R isozyme by FBP [63,64].
Arg405 (human R mutation Arg479→Pro) is located in the
phosphate-binding loop of the FBP pocket. Ala394
(human R mutation Ala468→Val) is located in the turn
between Cα2 and Cβ1, the region we propose as being
important for communication between the allosteric site
and the tetrameric interface.
Assuming that the E. coli enzyme is a representative apo
structure, the change in the position of Asp266 in the
quinternary complex may be a result of the metal ion
mediated allosteric relay mechanism for YPK [22,36]. We
propose that upon binding metal, and in the presence of
substrate, Asp266 moves into the coordination sphere of
the metal. This movement then triggers a change in the
protein structure across either or both subunit interfaces
resulting in the large domain rotations. Although these
large domain motions may not significantly alter the
position of key substrate or allosteric effector binding
residues, they induce subtle movements of the structure
in these regions and that may be all that is required to
increase the binding affinity for either substrate or
allosteric effector by 1–3 kcal/mol upon the binding of
the metal.
Biological implications 
The two main regulated steps in glycolysis are the phos-
phorylation of fructose-6-phosphate by phosphofructoki-
nase (PFK) to form fructose-1,6-bisphosphate (FBP),
the third step in glycolysis, and the dephosphorylation of
phosphoenolpyruvate (PEP) by pyruvate kinase (PK) to
form pyruvate (the final step prior to anaerobic fermen-
tation or oxidative decarboxylation). Both of these
enzymes are controlled by multiple allosteric ligands:
PFK is inhibited by ATP and by citrate, and activated
by AMP, while certain isozymes of PK are activated by
FBP. Transient inhibition of PK activity leads to the
accumulation of most glycolytic intermediates and an
enhancement of gluconeogenesis.
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The importance of the allosteric regulation of PK is
demonstrated by a variety of studies in both mammalian
and yeast systems. Studies of many tumor cell lines indi-
cate a reproducible isozyme shift towards regulated,
fetal isozymes of PK. In addition, an overall increase in
levels of glycolysis has been found in these tissues. The
alternatively expressed isozymes in tumor cells also
commonly show increases in phosphorylation levels,
another route to the regulation of the enzyme [5,7,9,10,
12]. In red blood cells, a large number of mutations in
the main PK isoform have been shown to interfere
with allosteric regulation. These mutations lead to an
inherited form of anemia caused by an increase in the
concentration of 2,3-diphosphoglycerate (a hemoglobin
regulator produced by diphosphoglycerate mutase from
the glycolytic intermediate 1,3-diphosphoglycerate), and
result in a decrease in the affinity of hemoglobin for
oxygen [65]. Finally, recent studies have demonstrated
that an enzyme that phosphorylates PK in yeast is an
important regulator of cell-cycle progression in that
organism [66].
The studies reported here describe the allosteric FBP-
binding site and the mode of PK activation by FBP.
They also directly demonstrate the basis for differences
in the regulatory properties of the enzyme produced by
the alternative splicing of a single exon in its primary
sequence. This exon contributes several residues to the
FBP-binding pocket and forms the majority of the
tetramer interface. This region also creates a pivot point
for the subunit movements seen when comparing the
activated and unactivated forms of the enzyme. The
conformational differences in the active site observed
between the activated, substrate-bound PK structures
described here, and the structure of a low affinity, inacti-
vated apoenzyme from Escherichia coli clearly demon-
strate that allosteric activation is limited to small
movements of a limited number of sidechains involved in
binding substrate and metal ions. 
Materials and methods
Purification 
PK was purified from S. cerevisiae PYK1-500 using a modification of
the previously described procedure [36]. This yeast strain contains the
plasmid pPYK101 and overexpresses PK. The purification involved two
chromatography steps, DEAE cellulose (Sigma) and phosphocellulose
(Sigma), and NH4SO4 backwashes. Briefly, DEAE cellulose was equili-
brated with 10 mM K2PO4, 5 mM EDTA, 5 mM β-mercaptoethanol
(BME), pH 7.0, and the lysate, prepared by osmotic rupture using lyti-
case, was applied. The resin was washed with the equilibration buffer
described above and the effluent solution containing the enzyme activ-
ity was then separated and adjusted to pH 6.0 using 1M HCl. A phos-
phocellulose slurry in 10 mM K2PO4, 5 mM EDTA, 5 mM BME, pH 6.0
was added to the DEAE effluent solution. After 1 h <0.6% of the total
activity remained unbound in the supernatant, and this was then dis-
carded. The phosphocellulose slurry was washed with 10 mM K2PO4,
25% glycerol, 5 mM EDTA, 5 mM BME, pH 6.0, and proteins were
then eluted from the column with a linear gradient from 0 to 0.6 M KCl
in 10 mM K2PO4, 25% glycerol, 5 mM EDTA, 5 mM BME, pH 6.0.
Fractions with greater than 190 units/ml PK activity (eluted between
0.35 to 0.45 M KCl) were pooled for further purification. The pooled
fractions were concentrated to greater than 10 mg/ml. The concen-
trated protein was then dialyzed overnight against 10 mM K2PO4, 25%
glycerol, 5 mM EDTA, 5 mM BME, pH 6.2 saturated with NH4SO4. The
precipitated protein was centrifuged and the supernatant removed. The
protein pellet was then washed with 10 mM K2PO4, 25% glycerol,
5 mM EDTA, 5 mM BME, pH 6.2 saturated with 56, 54, 48 and 44%
NH4SO4. The washes were performed in descending succession.
Supernatants with PK activity greater than 200 units/mg were com-
bined and concentrated to greater then 10 mg/ml. The purified enzyme,
at a concentration of 10–15 mg/ml, was stored at 4°C as a suspension
in 46% saturated NH4SO4, 200 mM KCl, 10 mM phosphate, 20%
glycerol, 5 mM BME, pH 6.2. The enzyme was desalted for further
experiments by centrifugation and resuspension of the pellet in 20%
glycerol, 200 mM KCl, 10 mM phosphate pH 6.2, and then passed
over a Pharmacia dextran 200 sizing column equilibrated with the same
buffer. The enzyme was found to be relatively unstable when stored in
the absence of NH4SO4, therefore only volumes of enzyme required for
immediate use were resuspended.
Steady-state kinetic studies
YPK activity was measured by a continuous assay coupled to lactate
dehydrogenase (LDH). The change in absorbance at 340 nm due to
oxidation of NADH was measured using either a Hewlet-Packard
7475A diode array or a Gilford 240 or 250 UV/VIS thermostated spec-
trophotometer. Kinetic assays for specific activity determinations con-
tained YPK (0.5 to 0.7 µg), MES (100 mM), glycerol (5%), KCl
(200 mM), MgCl2 (15 mM), ADP (5 mM), PEP (5 mM), FBP (1 mM),
NADH (175 µM), and LDH (20 µg). PG inhibition studies were per-
formed under the same assay conditions listed above except Mn2+ at
10 mM was substituted for Mg2+ and the FBP concentration was fixed
at 10 mM. The substrate PEP was varied from 5 to 200 mM at fixed,
variable PG concentrations. PG activation studies were performed by
varying PG concentrations at fixed, variable PEP concentrations in the
absence of FBP. Steady-state kinetic rates were determined by mea-
suring the slope of the tangent to the reaction progress curve. All initial
velocity data was first fit to both the Michaelis–Menten and the Hill
equations for the determination of the apparent Michaelis constants
(KM), Hill coefficients (nH), and maximal velocity (Vmax) using the
program Table Curve 2D (Jandel Scientific). PG inhibition data was
then fit to models for competitive, non-competitive and uncompetitive
inhibition using the program Table Curve 3D (Jandel Scientific).
Crystallization 
Crystallization experiments were carried out using the method of vapor
diffusion in hanging drops. Protein concentrations ranged from
4–12 mg/ml in the experiments. Two separate complexes of YPK were
co-crystallized. The first was a quaternary complex of YPK complexed
with PG (10 mM) and Mn2+ (10 mM) in 200 mM KCl. The second
complex was a quinternary complex similar to the first except that
10 mM FBP was added. The crystallization solution in the reservoir for
the quaternary complex co-crystallization had a volume of 300 µl and
was composed of 28–33% (w/v) PEG 8000, 200 mM sodium acetate,
100 mM sodium cacodylate pH 6.5. 2 µl of the protein solution and
2 ml of the reservoir solution were mixed and then equilibrated against
the reservoir at 4°C for 1–16 weeks before crystals appeared. The
dimensions of the crystals used were 0.4 mm × 0.2 mm × 0.2. The quin-
ternary complex co-crystallization was similar to that of the quaternary
complex, except that the best crystals were grown using a reservoir
with a volume of 600 µl, composed of 34–36% (w/v) PEG 8000,
50 mM sodium acetate, 100 mM sodium cacodylate pH 6.5. The crys-
tals were allowed to grow at 4°C but for a longer period of time, 2–6
months, before X-ray quality crystals were obtained. The quaternary
complex crystals grew in space group C2 with cell dimensions
a = 108.3, b = 106.4, c = 105.5 Å, β = 110.8°C, with two monomers
of PK forming the asymmetric unit. The quinternary complex crystals
also grew in space group C2 with cell dimensions a = 110.4,
b = 104.0, c = 112.2 Å, β = 112.3°C, and two monomers of PK in an
asymmetric unit.
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Data collection
Diffraction data for the quinternary complex were collected on an
RAXIS II area detector. The X-ray source was CuKα radiation from a
Rigaku RU-200 rotating anode operated at 50 kV and 100 mA, with a
graphite monochromator. The crystal form of the quinternary complex
was mounted in a capillary tube and data were collected at 10°C. Dif-
fraction data for the quaternary complex was collected at the
Brookhaven National Synchrotron Light Source on beamline X12-C
using a MAR RESEARCH area detector. The crystal of the quaternary
complex was flash-cooled at –175°C after equilibration of the crystal
with a cryo-solvent containing 20% glycerol, 40 % PEG 8000,
200 mM KCl, and 10 mM phosphate buffer at pH 6.5. All data was
processed using DENZO and SCALEPACK [67] (results shown in
Table 1).
Molecular replacement 
The structure of YPK was solved by molecular replacement (MR) with
the AMORE software package [68]. The coordinates of PK from rabbit
muscle were used as the search model. All the sidechains in the model
that were known from sequence alignment to be different from yeast
enzyme were converted to alanine using the modeling package
QUANTA. For the rotation function only Patterson densities inside a
spherical shell of inner and outer radii of 3 Å and 35 Å were used in
Patterson map superpositions.
For the quinternary enzyme complex, the structure was solved using an
enzyme monomer as the search model in MR (the asymmetric unit is a
pair of subunits). Within the highest rotation peaks the first and third
are related by 180°C. These two solutions were assumed to represent
orientations of the two molecules in the asymmetric unit. The locations
of the two molecules were then determined by the corresponding
translation function calculation. The highest (and next highest) correla-
tion coefficients calculated for peaks in the translation maps for the two
orientations are 24.1 and 22.3 (18.6), respectively. These highest cor-
relation coefficients also correspond to the lowest R factors. For the
relative y separation between the two molecules, the translation func-
tion for the second orientation was calculated with the first solution
fixed, and yielded a single large peak with correlation coefficient of
35.8. Rigid-body refinement of the orientation and position of the two
molecules using data between 10.0 Å and 3.0 Å resulted in a crystallo-
graphic R factor of 47.7%
For the quaternary enzyme complex, the structure was solved using a
monomer of the refined quinternary complex as a the search model in
MR. The highest two peaks in the rotation search have correlation coef-
ficients of 23.1 and 20.5 and are related by a rotation of 180°C. The
next highest peak is considerably weaker at 8.8. The translation search
solutions for these orientations yielded peaks with correlation coeffi-
cients of 37.9 and 32.4. By fixing on monomer and repeating the trans-
lation search for the other monomer and vice versa, further refinement
of these positions were obtained with correlation coefficients of 60.1
and 60.7. Rigid-body refinement of the orientation and position of the
two molecules using data between 10.0 Å and 3.5 Å resulted in a crys-
tallographic R factor of 36.1%.
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Table 1
Data collection and refinement statistics. 
Quinternary complex Quaternary complex
(+FBP) (–FBP)
Space group C2 C2
Cell parameters (Å) (a, b, c) 110.4, 104.0, 112.2 108.3, 106.4, 105.5
β (°) 112.3 110.8
Crystalline forms Monoclinic Monoclinic
No. molecules/asymmetric unit 2 2
No. reflections 66 108 94 232
No. unique reflections 19 294 19 331
Rsym (%) 6.5 10.8
Refinement
Resolution range (Å) 100–3.0 100–3.0
Unique reflections (F >2σ) 17 327 18 430
Completeness (%) 91 85
R factor (no σ cut-off) (%) 21.8 (24.8) 22.7 (24.8)
R free (no σ cut-off) (%) 32.3 (34.9) 34.1 (34.3)
No. of protein atoms in final model 7524 7476
(no solvent molecules included)
Ramachandran plot
core (%) 80.5 76.3
allowed (%) 16.6 19.2
generous (%) 2.1 3.5
disallowed (%) 0.8 0.9
Rmsd
bonds (Å) 0.009 0.013
angles (°) 1.868 1.736
dihedrals (°) 27.69 24.480
impropers (°) 0.930 1.571
Average B factor (Å2) 25 14
B factor (Å2)/occupancy (%)
FBP 28/87 –
Phosphoglycolate 35/87 16/93
Mn2+ 18/100 10/100
K+ 29/84 15/100
Modeling and refinement 
Prior to any refinement 10% of the data was set aside for cross valida-
tion with Rfree. Refinement of the quinternary complex was performed
with X-PLOR [69]. Following an initial positional refinement PG, Mn2+,
and K+ were built into the active site using a Fo–Fc map contoured at
1.7σ. Iterative rounds of simulated annealing, torsional and positional
refinement failed to result in a significant drop in Rfree until noncrystallo-
graphic symmetry (NCS) restraints and a bulk-solvent correction were
employed. NCS restraints were applied by grouping the A and C
domains separately from the B domains. This was to account for a
small shift in the positions between the two B domains relative to the
rest of the protein. The rms deviation between NCS related Cα atoms
was 0.17 Å for the A and C domains, and 0.13 Å for the B domains.
2Fo–Fc and Fo–Fc maps were used to manually rebuild sidechains and
adjust the model. After a group B refinement the R factor was 23.4%
and Rfree was 34.8%. At this point FBP was built into the allosteric site
using a Fo–Fc map contoured at 3.5σ. The map presented strong
density for the two phosphate groups of FBP, and the bridging ribose
sugar ring. Occupancy refinement for all modeled ligands was per-
formed to confirm their placement in the electron density. The final
model for the asymmetric unit of the activated quinternary complex con-
tains two FBP molecules, two PG molecules, two Mn2+ ions, two K+
ions, and two protein subunits consisting of 500 residues each (except
for the loop of residues 11–16 and turn of residues 160–161 in both
subunits and the turn of residues 99–101 in the second subunit).
Refinement of the quaternary complex was straight forward (Table 1).
NCS restraints were employed in XPLOR with rounds of simulated
annealing, torsional and positional refinement. 2Fo–Fc and Fo–Fc maps
were used to check and adjust the model. The R factor, Rfree and
Ramachandran plots were used to gauge the progression of the refine-
ment. Strong difference density (>4σ) was present in the active site for
the two cations and PG, and these were built into the model. There
was no difference density in the FBP-binding site and the loop of
residues 446–452 was not present in the 2Fo–Fc map. Also, no density
was present for the loop of residues 485–493. These residues were
removed from the model in both subunits.
There are four to five Ramachandran outliers per subunit (500
residues/subunit total). One of these is present in a turn of the A
domain (Lys233) and is well defined in the density. The remaining
outliers are in less well-defined loops, primarily in the B domain.
Overall the density of the B domain is of poorer quality, as illustrated
by higher B factors and a large proportion of generously allowed
Ramachandran angles in this region. NCS restraints in this region
were used with caution but still resulted in improvement of the struc-
ture as monitored by Rfree.
Accession numbers
Coordinates for the structures of the quaternary and quinternary com-
plexes have been deposited in the PDB with ID codes 1A3X and
1A3W, respectively.
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